{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:55:47Z","timestamp":1790265347379,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T00:00:00Z","timestamp":1550880000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/jac\/dkz015","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T12:06:45Z","timestamp":1547467605000},"page":"1430-1437","source":"Crossref","is-referenced-by-count":50,"title":["Oral fosfomycin for the treatment of chronic bacterial prostatitis"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0239","authenticated-orcid":false,"given":"Ilias","family":"Karaiskos","sequence":"first","affiliation":[{"name":"1st Department of Internal Medicine & Infectious Diseases, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambrini","family":"Galani","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine & Infectious Diseases, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vissaria","family":"Sakka","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine, Red Cross General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Gkoufa","sequence":"additional","affiliation":[{"name":"1st Department of Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odysseas","family":"Sopilidis","sequence":"additional","affiliation":[{"name":"3rd Urologic Clinic, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Chalikopoulos","sequence":"additional","affiliation":[{"name":"3rd Urologic Clinic, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Alivizatos","sequence":"additional","affiliation":[{"name":"3rd Urologic Clinic, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Giamarellou","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine & Infectious Diseases, Hygeia General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"2019042309335748300_dkz015-B1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1086\/652861","article-title":"Treatment of bacterial prostatitis","volume":"50","author":"Lipsky","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019042309335748300_dkz015-B2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/jama.282.3.236","article-title":"NIH consensus definition and classification of prostatitis","volume":"282","author":"Krieger","year":"1999","journal-title":"JAMA"},{"key":"2019042309335748300_dkz015-B3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00345-013-1055-x","article-title":"Bacterial prostatitis","volume":"31","author":"Wagenlehner","year":"2013","journal-title":"World J Urol"},{"key":"2019042309335748300_dkz015-B4","author":"Bonkat"},{"key":"2019042309335748300_dkz015-B5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bju.13101","article-title":"Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis\/chronic pelvic pain syndrome: a consensus guideline","volume":"116","author":"Rees","year":"2015","journal-title":"BJU Int"},{"key":"2019042309335748300_dkz015-B6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat of multidrug-resistant Gram-negative bacteria in urology","volume":"12","author":"Zowawi","year":"2015","journal-title":"Nat Rev Urol"},{"key":"2019042309335748300_dkz015-B7","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/AAC.06060-11","article-title":"In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010","volume":"56","author":"Sanchez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309335748300_dkz015-B8","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019042309335748300_dkz015-B9","doi-asserted-by":"crossref","first-page":"1404813.","DOI":"10.1155\/2018\/1404813","article-title":"Oral fosfomycin for the treatment of acute and chronic bacterial prostatitis caused by multidrug-resistant Escherichia coli","volume":"2018","author":"Zhanel","year":"2018","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2019042309335748300_dkz015-B10","article-title":"Antimicrobial therapy for chronic bacterial prostatitis","volume":"8","author":"Perletti","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2019042309335748300_dkz015-B11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jiac.2016.01.010","article-title":"Fosfomycin: resurgence of an old companion","volume":"22","author":"Sastry","year":"2016","journal-title":"J Infect Chemother"},{"key":"2019042309335748300_dkz015-B12","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s40265-013-0143-y","article-title":"Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"2019042309335748300_dkz015-B13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","article-title":"Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches","volume":"15","author":"Karaiskos","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2019042309335748300_dkz015-B14","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/cid\/cit704","article-title":"Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019042309335748300_dkz015-B15","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1093\/clind\/15.Supplement_1.S216","article-title":"Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration","volume":"15 Suppl 1","author":"Rubin","year":"1992","journal-title":"Clin Infect Dis"},{"key":"2019042309335748300_dkz015-B16","first-page":"492","article-title":"Bacteriologic localization patterns in bacterial prostatitis and urethritis","volume":"5","author":"Meares","year":"1968","journal-title":"Invest Urol"},{"key":"2019042309335748300_dkz015-B17","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMcp060423","article-title":"Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome","volume":"355","author":"Schaeffer","year":"2006","journal-title":"N Engl J Med"},{"key":"2019042309335748300_dkz015-B18","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.ijantimicag.2007.07.044","article-title":"Evaluation of acute and chronic bacterial prostatitis and diagnostic management of chronic prostatitis\/chronic pelvic pain syndrome with special reference to infection\/inflammation","volume":"31 Suppl 1","author":"Weidner","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309335748300_dkz015-B19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.diii.2012.03.009","article-title":"Imaging in lower urinary tract infections","volume":"93","author":"Schull","year":"2012","journal-title":"Diagn Interv Imaging"},{"key":"2019042309335748300_dkz015-B20"},{"key":"2019042309335748300_dkz015-B21","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Eighth Edition: M100","year":"2018"},{"key":"2019042309335748300_dkz015-B22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2019042309335748300_dkz015-B23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019042309335748300_dkz015-B24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijantimicag.2008.03.014","article-title":"Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis","volume":"32","author":"Naber","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309335748300_dkz015-B25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0090-4295(03)00565-X","article-title":"Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study","volume":"62","author":"Bundrick","year":"2003","journal-title":"Urology"},{"key":"2019042309335748300_dkz015-B26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2009.08.018","article-title":"Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment","volume":"35","author":"Katsarolis","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309335748300_dkz015-B27"},{"key":"2019042309335748300_dkz015-B28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jmii.2012.05.012","article-title":"Changing antibiotic susceptibilities of community-acquired uropathogens in Greece, 2005-2010","volume":"46","author":"Maraki","year":"2013","journal-title":"J Microbiol Immunol Infect"},{"key":"2019042309335748300_dkz015-B29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/1120009X.2016.1158937","article-title":"Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections","volume":"29","author":"Trad","year":"2017","journal-title":"J Chemother"},{"key":"2019042309335748300_dkz015-B30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO\u00b7SENS study revisited","volume":"39","author":"Kahlmeter","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309335748300_dkz015-B31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2019042309335748300_dkz015-B32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309335748300_dkz015-B33","doi-asserted-by":"crossref","first-page":"e13021","DOI":"10.1111\/and.13021","article-title":"Pharmacodynamic and pharmacokinetic studies and prostatic tissue distribution of fosfomycin tromethamine in bacterial prostatitis or normal rats","volume":"50","author":"Fan","year":"2018","journal-title":"Andrologia"},{"key":"2019042309335748300_dkz015-B34","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.02611-15","article-title":"Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis","volume":"60","author":"Los-Arcos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019042309335748300_dkz015-B35","doi-asserted-by":"crossref","first-page":"414.","DOI":"10.1016\/j.ijantimicag.2016.02.009","article-title":"Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: successful treatment with prolonged fosfomycin therapy","volume":"47","author":"Gian","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309335748300_dkz015-B36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for treatment of prostatitis: new tricks for old dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019042309335748300_dkz015-B37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","article-title":"Persistent extended-spectrum \u03b2-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline","volume":"45","author":"Cunha","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2019042309335748300_dkz015-B38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00345-013-1145-9","article-title":"The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study","volume":"32","author":"Bartoletti","year":"2014","journal-title":"World J Urol"},{"key":"2019042309335748300_dkz015-B39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/aja.2012.40","article-title":"Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis","volume":"14","author":"Zhao","year":"2012","journal-title":"Asian J Androl"},{"key":"2019042309335748300_dkz015-B40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0094-0143(21)01810-3","article-title":"Ultrasonographic findings in prostatitis","volume":"16","author":"Doble","year":"1989","journal-title":"Urol Clin North Am"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/5\/1430\/28501338\/dkz015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T05:39:49Z","timestamp":1662788389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/5\/1430\/5363231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,22]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz015","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,2,22]]}}}